Decheng Capital LLC 13F Holdings · Q2 2026
Decheng Capital LLC reported 14 securities worth $731.75M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: CGON (61.87%), NUVB (20.15%), AARD (3.08%). Among its top 25 positions this quarter: 1 new, 3 trimmed, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | CGON | CG ONCOLOGY INC | $452.7M | 61.87% | 6.4M | Hold |
| 2 | NUVB | Nuvation Bio Inc. | $147.4M | 20.15% | 26.0M | Hold |
| 3 | AARD | AARDVARK THERAPEUTICS INC | $22.6M | 3.08% | 3.9M | Hold |
| 4 | ACRS | Aclaris Therapeutics, Inc. | $21.4M | 2.92% | 4.0M | Hold |
| 5 | UPB | Upstream Bio Inc. | $18.9M | 2.58% | 2.7M | Hold |
| 6 | RCUS | Arcus Biosciences, Inc | $14.3M | 1.96% | 464,779 | Trimmed |
| 7 | EQ | Equillium Inc. | $14.2M | 1.94% | 4.4M | Hold |
| 8 | RVMD | REVOLUTION MEDICINES INC(NSM) | $9.9M | 1.35% | 52,667 | Trimmed |
| 9 | LYEL | Lyell Immunopharma, Inc. | $9.7M | 1.33% | 692,050 | Hold |
| 10 | BYSI | BeyondSpring Inc. | $6.7M | 0.91% | 3.8M | Hold |
| 11 | ZNTL | Zentalis Pharmaceuticals Inc. | $6.4M | 0.88% | 1.3M | Hold |
| 12 | NAMS | NEWAMSTERDAM PHARMA CO NV | $6.0M | 0.82% | 176,887 | Trimmed |
| 13 | PYXS | Pyxis Oncology, Inc (formerly Apexigen) | $983,698 | 0.13% | 326,810 | Hold |
| 14 | TNGX | TANGO THERAPEUTICS INC | $625,200 | 0.09% | 20,000 | New |
| 15 | KRYS | KRYSTAL BIOTECH INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR